Insuman Comb 50

Insulin human, the active ingredient in Insuman Comb 50, is an insulin presented as a subcutaneous formulation for subcutaneous use. It replaces deficient endogenous insulin and helps control blood glucose levels in individuals with type 1 or type 2 diabetes mellitus.

GNH USA supplies Insuman Comb 50 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution through reliable cold‑chain logistics.

Insuman Comb 50 provides insulin therapy for diabetes mellitus, acting to replace or supplement endogenous insulin.

- Type 1 diabetes mellitus: improves glycemic control by supplying the insulin the body cannot produce. - Type 2 diabetes mellitus: assists in achieving target blood glucose when pancreatic insulin secretion is insufficient. - Insulin‑dependent hyperglycemia: offers basal and prandial coverage to maintain stable glucose levels.

Insuman Comb 50 may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypoglycemia: low blood glucose symptoms such as sweating, tremor, and confusion. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: increase in body weight due to anabolic effects of insulin. - Lipodystrophy: localized fat accumulation or loss at injection sites.

Serious or Rare Side Effects: - Severe hypoglycemia: loss of consciousness or seizures requiring emergency assistance. - Anaphylactic reaction: hives, airway swelling, or anaphylaxis needing immediate treatment. - Insulin allergy: systemic rash or urticaria after injection. - Hypokalemia: low potassium levels observed in rare cases.

When using Insuman Comb 50, several precautions should be observed to ensure safe and effective therapy. - Dose adjustment: tailor insulin dose based on regular blood glucose monitoring and carbohydrate intake. - Renal impairment: monitor closely as reduced clearance may increase hypoglycemia risk. - Hepatic impairment: use with caution; altered metabolism may affect insulin requirements. - Pregnancy: consult healthcare provider; insulin is the preferred agent but dosing may need modification. - Hypoglycemia risk: educate patients on recognizing and treating low blood glucose promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insuman Comb 50 can interact with other medicines, influencing its glucose‑lowering effect or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycemia symptoms, complicating detection. - MAO inhibitors: can potentiate insulin’s hypoglycemic action. - Concomitant use of other insulins: increases risk of severe hypoglycemia.

Moderate Interactions (Monitor Closely): - Sulfonylureas or other oral hypoglycemics: additive glucose‑lowering effect may require dose adjustment. - Thiazolidinediones: may increase fluid retention and weight gain. - ACE inhibitors or ARBs: may enhance insulin sensitivity, potentially altering dose needs.